SBI Healthcare Opportunities Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹3,611 Cr
Expense Ratio
0.90%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹471.98, Assets Under Management (AUM) of 3610.51 Crores, and an expense ratio of 0.9%.
- SBI Healthcare Opportunities Fund Direct Growth has given a CAGR return of 18.24% since inception.
- The fund's asset allocation comprises around 96.96% in equities, 0.00% in debts, and 3.04% in cash & cash equivalents.
- You can start investing in SBI Healthcare Opportunities Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+21.64%
+17.55% (Cat Avg.)
3 Years
+23.93%
+18.10% (Cat Avg.)
5 Years
+26.46%
+22.46% (Cat Avg.)
10 Years
+12.57%
+12.75% (Cat Avg.)
Since Inception
+18.24%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹3,500.72 Cr | 96.96% |
| Others | ₹109.79 Cr | 3.04% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹485.72 Cr | 13.45% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹241.33 Cr | 6.68% |
| Divi's Laboratories Ltd | Equity | ₹216.58 Cr | 6.00% |
| Cipla Ltd | Equity | ₹173.06 Cr | 4.79% |
| Lupin Ltd | Equity | ₹170.35 Cr | 4.72% |
| Lonza Group Ltd ADR | Equity | ₹158.28 Cr | 4.38% |
| Mankind Pharma Ltd | Equity | ₹135.79 Cr | 3.76% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹134.32 Cr | 3.72% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹127.72 Cr | 3.54% |
| Ami Organics Ltd | Equity | ₹122.04 Cr | 3.38% |
| Poly Medicure Ltd | Equity | ₹121.24 Cr | 3.36% |
| Fortis Healthcare Ltd | Equity | ₹120.12 Cr | 3.33% |
| Aether Industries Ltd | Equity | ₹116.34 Cr | 3.22% |
| Treps | Cash - Repurchase Agreement | ₹114.02 Cr | 3.16% |
| Abbott India Ltd | Equity | ₹110.59 Cr | 3.06% |
| Laurus Labs Ltd | Equity | ₹110.41 Cr | 3.06% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹106.37 Cr | 2.95% |
| Alkem Laboratories Ltd | Equity | ₹97.63 Cr | 2.70% |
| Torrent Pharmaceuticals Ltd | Equity | ₹96.84 Cr | 2.68% |
| Aurobindo Pharma Ltd | Equity | ₹92.84 Cr | 2.57% |
| Rainbow Childrens Medicare Ltd | Equity | ₹89.71 Cr | 2.48% |
| Gland Pharma Ltd | Equity | ₹86.69 Cr | 2.40% |
| Biocon Ltd | Equity | ₹68.34 Cr | 1.89% |
| Suven Pharmaceuticals Ltd | Equity | ₹62.22 Cr | 1.72% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹60.43 Cr | 1.67% |
| Concord Biotech Ltd | Equity | ₹46.49 Cr | 1.29% |
| Pfizer Ltd | Equity | ₹40.05 Cr | 1.11% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹39.4 Cr | 1.09% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹36.2 Cr | 1.00% |
| Gufic Biosciences Ltd | Equity | ₹33.63 Cr | 0.93% |
| Net Receivable / Payable | Cash - Collateral | ₹-7.21 Cr | 0.20% |
| 182 DTB 05062025 | Bond - Gov't/Treasury | ₹2.97 Cr | 0.08% |
Allocation By Market Cap (Equity)
Large Cap Stocks
26.93%
Mid Cap Stocks
28.72%
Small Cap Stocks
36.93%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹3,262.34 Cr | 90.36% |
| Basic Materials | ₹238.38 Cr | 6.60% |
Risk & Performance Ratios
Standard Deviation
This fund
14.93%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
1.11
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Fund Managers
Tanmaya Desai
Since June 2011
Additional Scheme Detailsas of 31st March 2025
ISIN INF200K01UP2 | Expense Ratio 0.90% | Exit Load No Charges | Fund Size ₹3,611 Cr | Age 12 years 3 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
About the AMC
SBI Mutual Fund
Total AUM
₹10,17,433 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Other Funds by SBI Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of SBI Healthcare Opportunities Fund Direct Growth?
What are the returns of SBI Healthcare Opportunities Fund Direct Growth?
What is the portfolio composition of SBI Healthcare Opportunities Fund Direct Growth?
Who manages the SBI Healthcare Opportunities Fund Direct Growth?
- Tanmaya Desai
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
SBI Healthcare Opportunities Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹3,611 Cr
Expense Ratio
0.90%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
Risk Level
Your principal amount will be at Very High Risk
About this fund
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹471.98, Assets Under Management (AUM) of 3610.51 Crores, and an expense ratio of 0.9%.
- SBI Healthcare Opportunities Fund Direct Growth has given a CAGR return of 18.24% since inception.
- The fund's asset allocation comprises around 96.96% in equities, 0.00% in debts, and 3.04% in cash & cash equivalents.
- You can start investing in SBI Healthcare Opportunities Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+21.64%
+17.55% (Cat Avg.)
3 Years
+23.93%
+18.10% (Cat Avg.)
5 Years
+26.46%
+22.46% (Cat Avg.)
10 Years
+12.57%
+12.75% (Cat Avg.)
Since Inception
+18.24%
— (Cat Avg.)
Portfolio Summaryas of 31st March 2025
| Equity | ₹3,500.72 Cr | 96.96% |
| Others | ₹109.79 Cr | 3.04% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹485.72 Cr | 13.45% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹241.33 Cr | 6.68% |
| Divi's Laboratories Ltd | Equity | ₹216.58 Cr | 6.00% |
| Cipla Ltd | Equity | ₹173.06 Cr | 4.79% |
| Lupin Ltd | Equity | ₹170.35 Cr | 4.72% |
| Lonza Group Ltd ADR | Equity | ₹158.28 Cr | 4.38% |
| Mankind Pharma Ltd | Equity | ₹135.79 Cr | 3.76% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹134.32 Cr | 3.72% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹127.72 Cr | 3.54% |
| Ami Organics Ltd | Equity | ₹122.04 Cr | 3.38% |
| Poly Medicure Ltd | Equity | ₹121.24 Cr | 3.36% |
| Fortis Healthcare Ltd | Equity | ₹120.12 Cr | 3.33% |
| Aether Industries Ltd | Equity | ₹116.34 Cr | 3.22% |
| Treps | Cash - Repurchase Agreement | ₹114.02 Cr | 3.16% |
| Abbott India Ltd | Equity | ₹110.59 Cr | 3.06% |
| Laurus Labs Ltd | Equity | ₹110.41 Cr | 3.06% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹106.37 Cr | 2.95% |
| Alkem Laboratories Ltd | Equity | ₹97.63 Cr | 2.70% |
| Torrent Pharmaceuticals Ltd | Equity | ₹96.84 Cr | 2.68% |
| Aurobindo Pharma Ltd | Equity | ₹92.84 Cr | 2.57% |
| Rainbow Childrens Medicare Ltd | Equity | ₹89.71 Cr | 2.48% |
| Gland Pharma Ltd | Equity | ₹86.69 Cr | 2.40% |
| Biocon Ltd | Equity | ₹68.34 Cr | 1.89% |
| Suven Pharmaceuticals Ltd | Equity | ₹62.22 Cr | 1.72% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹60.43 Cr | 1.67% |
| Concord Biotech Ltd | Equity | ₹46.49 Cr | 1.29% |
| Pfizer Ltd | Equity | ₹40.05 Cr | 1.11% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹39.4 Cr | 1.09% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹36.2 Cr | 1.00% |
| Gufic Biosciences Ltd | Equity | ₹33.63 Cr | 0.93% |
| Net Receivable / Payable | Cash - Collateral | ₹-7.21 Cr | 0.20% |
| 182 DTB 05062025 | Bond - Gov't/Treasury | ₹2.97 Cr | 0.08% |
Allocation By Market Cap (Equity)
Large Cap Stocks
26.93%
Mid Cap Stocks
28.72%
Small Cap Stocks
36.93%
Allocation By Credit Quality (Debt)
AAA
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹3,262.34 Cr | 90.36% |
| Basic Materials | ₹238.38 Cr | 6.60% |
Risk & Performance Ratios
Standard Deviation
This fund
14.93%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
1.11
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Fund Managers
Tanmaya Desai
Since June 2011
Additional Scheme Detailsas of 31st March 2025
ISIN INF200K01UP2 | Expense Ratio 0.90% | Exit Load No Charges | Fund Size ₹3,611 Cr | Age 12 years 3 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
About the AMC
SBI Mutual Fund
Total AUM
₹10,17,433 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Other Funds by SBI Mutual Fund
Related Articles
Still got questions?
We're here to help.
What is the current NAV of SBI Healthcare Opportunities Fund Direct Growth?
What are the returns of SBI Healthcare Opportunities Fund Direct Growth?
What is the portfolio composition of SBI Healthcare Opportunities Fund Direct Growth?
Who manages the SBI Healthcare Opportunities Fund Direct Growth?
- Tanmaya Desai
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Track all you investments in one place
Download Wealth Monitor App
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
